949527-24-6

Basic information

• Product Name: [4-(4-chloro-5-phenyl-thieno[2,3-d]pyrimidin-2-yl)-phenyl]-dimethyl-amine
• Synonyms: [4-(4-chloro-5-phenyl-thieno[2,3-d]pyrimidin-2-yl)-phenyl]-dimethyl-amine
• CAS NO: 949527-24-6
• Molecular Weight: 365.886
• Mol File: 949527-24-6.mol
• Article Data: 3

Chemical Properties

• CAS DataBase Reference: [4-(4-chloro-5-phenyl-thieno[2,3-d]pyrimidin-2-yl)-phenyl]-dimethyl-amine(CAS DataBase Reference)
• NIST Chemistry Reference: [4-(4-chloro-5-phenyl-thieno[2,3-d]pyrimidin-2-yl)-phenyl]-dimethyl-amine(949527-24-6)
• EPA Substance Registry System: [4-(4-chloro-5-phenyl-thieno[2,3-d]pyrimidin-2-yl)-phenyl]-dimethyl-amine(949527-24-6)

Safety Data

• Hazardous Substances Data: 949527-24-6(Hazardous Substances Data)

Upstream product

• 98-86-2 acetophenone 
• 1622230-18-5 C₂₀H₁₇N₃OS 
• 67171-55-5 2-amino-4-phenylthiophene-3-carboxylic acid methyl ester 
• 14505-27-2 Methyl-α-cyano-β-methyl-β-phenylacrylat 

Downstream Products

• 1622230-23-2 C₂₀H₁₉N₅S 

Relevant articles and documents

Synthesis and biological evaluation of novel thieno[2,3-d[pyrimidine-based FLT3 inhibitors as anti-leukemic agents

The most common mutations in acute myeloid leukemia (AML) are those that cause the activation of FMS-like tyrosine kinase 3 (FLT3). Therefore, FLT3 is regarded as a potential target for the treatment of AML. A novel series of thieno[2,3-d]pyrimidine-based analogs was designed and synthesized as FLT3 inhibitors. All synthesized compounds were assayed for the tyrosine kinase activity of FLT3 and growth inhibitory activity in four human leukemia cell lines (THP1, MV4-11, K562, and HL-60). Among these compounds, compound 17a, which possesses relatively short and simple substituents at the C6 position of thieno[2,3-d]pyrimidine, emerged as the most promising anti-leukemic agent. Compound 17a exhibited potent inhibition of FLT3-positive leukemic cell growth and of the FLT3 D835Y kinase; such inhibition is required for the successful treatment of AML. The data supports the further investigation of this class of compounds as potential anti-leukemic agents.

NOVEL THIENOPYRIMIDINE DERIVATIVES OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF, PROCESS FOR THE PREPARATION THEREOF AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME

The present invention relates to a novel thienopyrimidine derivative having an excellent anti? inflammatory and anti-cancer activity, or a pharmaceutically acceptable salt thereof, a process for the preparation thereof and a pharmaceutical composition comprising the same. The compound according to the present invention strongly inhibits IKB kinase-β (IKK-β) involved in the activation of a transcriptional factor, NF-κB, which is associated with inducing various immune and inflammatory diseases, whereby a composition comprising the compound is a useful therapeutic agent against inflammatory diseases, in particular, arthritis and cancer.